AbbVie Denies Revolution Medicines Acquisition Talks, Impacting Stock

AbbVie (ABBV) shares declined 3.98% after the company publicly denied being in advanced talks to acquire cancer-drug developer Revolution Medicines.

• The stock closed at $224.13 on January 08, 2026.
• The denial reversed positive sentiment from the previous day, which was driven by Wall Street Journal speculation about the potential acquisition.
• Shares of Revolution Medicines also experienced a downturn following the announcement.